Lantidra is a donor-derived pancreatic islet product, not a stem-cell-derived therapy. FDA approved it in June 2023 for a restricted group of adults with type 1 diabetes who cannot approach their target HbA1c because of recurrent severe hypoglycemia despite intensive management and education. 1
Its proper name is donislecel-jujn. The existence of this approval is important when discussing “the first diabetes cell therapy,” but it does not mean that every newer cell product shares the same authorization.
What is being transplanted?
The product contains insulin-producing islets from a deceased donor. That distinguishes it from the stem-cell-derived cells investigated in zimislecel and from modified-cell proof-of-concept programs. 2 3
Cell source is not merely a manufacturing footnote. It identifies the actual product and the evidence that belongs to it. A study of donor-derived islets cannot be counted as a trial of a separately manufactured stem-cell-derived candidate.
The comparison page keeps those categories separate without claiming that source alone determines which approach is better.
The indication is not “anyone with type 1 diabetes”
FDA's product record identifies a specific risk-and-control problem despite intensive management. 1
That should remain in the first explanation of the therapy, not appear only in a footnote beneath an insulin-free headline. A benefit-risk decision for a restricted transplant population should not be generalized to people doing well with their existing management.
This article cannot determine whether an individual meets the indication. It also does not advise changing insulin or other medication. It supplies the regulator's scope so readers do not confuse approval with a universal recommendation.
What did the label's studies show?
The label describes thirty participants in two uncontrolled studies, with some receiving more than one infusion. Twenty-five achieved a period of insulin independence and five did not. These are not uniform-duration outcomes after one identical treatment exposure. 2
That distinction is sufficient to prevent a misleading comparison with a fixed one-year endpoint in a different program. “Ever achieved a period of independence” and “independent at day 365 in a defined full-dose cohort” are different measures, even if both involve external insulin use.
We have not converted duration categories into a new pooled success percentage. The label's reporting context and each participant's observation period matter more than a single promotional fraction.
Why immunosuppression changes the benefit-risk question
Lantidra requires concomitant immunosuppression. Its labeling reports serious adverse reactions in most participants and addresses risks associated with infusion and immune-suppressing treatment. 2
This does not mean that a clinically meaningful benefit is impossible. It means that insulin independence cannot be read as “no more medication and no more medical risk.” The transplant pathway can exchange one burden for another, and that exchange has to be evaluated in the intended population.
NIDDK's transplant information explains why immune suppression is used and why its risks are a central part of transplant care. 4
Why this is not approval of a generic “stem-cell cure”
The authorized name, cell source and indication belong together. A clinic cannot make an unrelated cell intervention equivalent to Lantidra merely by describing it as regenerative or insulin-producing.
Similarly, the zimislecel report concerns a separate investigational product. UP421 and SC451 address another research strategy. Their evidence should not be merged with Lantidra's approval to create a composite treatment that no single study or regulator has established. 3 5
Access and cost
FDA approval establishes a U.S. regulatory fact. It does not establish a particular center's capacity, a payer's coverage decision or the complete cost of assessment, infusion, medication and follow-up. We have not verified a patient-specific price and do not invent one.
The same distinction applies internationally. U.S. authorization does not automatically establish the authorized status of a product or service in another jurisdiction.
The useful conclusion
Lantidra shows that a real donor-islet approval exists for a selected adult population. It does not show that all type 1 diabetes has become curable through a generic cell injection.
The cell-therapy hub places that approval beside investigational approaches, and the insulin-independence explainer explains what the outcomes mean without turning them into a universal cure rate.